02.23.21

FCI Ophthalmics Announces Availability of LacriJet for Monocanalicular Nasolacrimal Intubation

Source: FCI Ophthalmics

FCI Ophthalmics announced the launch of the LacriJet in the United States. It is the first, self-retaining monocanalicular nasolacrimal intubation preloaded on a single use injector, according to FCI Ophthalmics.

LacriJet consists of a single use injector handpiece into which a silicone tube is preloaded inside a metallic probe. LacriJet has been specifically designed to reduce operating time during intubation and removal of the device. It is indicated for epiphora, congenital nasolacrimal duct obstruction (CNLDO), and canalicular laceration.

LacriJet is first introduced into the nasolacrimal duct. Once in position, the sliding piston is retracted, and the silicone intubation is released. It is maintained in place at the punctum by a plug-like fixation head. No nasal retrieval, knots or sutures are needed.

The device:

  • features an exclusive new injection system
  • is available in 7 lengths
  • has a 3 mm plug collarette
  • is sterile and single use

Benefits: 

  • Preloaded device simplifies surgical technique
  • Injector protects stent during insertion
  • Requires less manipulation

 

Recent Content